United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roblox

Upwork Inc

Got cash? Here's how three high-flying growth stocks can make you rich.

3 Revolutionary Top Stocks to Buy Now

AbbVie

Gilead Sciences

I discuss 3 large cap pharma stocks that are yielding about 4.5% or more and are undervalued based on P/E ratio.

3 Pharma Dividend Growth Stocks Yielding 4.5%

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $PFE #MassGeneralBrigham--Mediar Therapeutics completes seed extension funding round with participation from Pfizer Ventures and Ono Venture Investment.

Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments

AstraZeneca

Novavax

These COVID Stocks Could Be Hurt by a Global Raw Material Shortage

Eli Lilly

Merck

An easily overlooked provision in the legislation could be bad news for four drugmakers, in particular.

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

Moderna

They both have plenty to offer investors.

Better COVID Stock: Moderna vs. Pfizer

Wuxi Biologics Cayman Inc

Pfizer Inc has decided to stop producing biosimilar products in China and sell a unit in the eastern city of Hangzhou to WuXi Biologics Inc, the U.S. drugmaker said on Wednesday.

Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics

BioNTech SE

Pfizer is looking to turn its lucrative coronavirus vaccine into an even bigger cash cow. The drugmaker sees a “significant opportunity” to charge more for the groundbreaking shot once it gets to the other side of the COVID-19 pandemic, one top executive says.

Pfizer sees ‘opportunity' to hike price for COVID-19 vaccine, CFO says

Drug companies have underperformed the broad market for several years. Value investment has been on the wane since the Great Recession but may be making a comeback.

Pfizer: Forget About Momentum And Start Buying Value

Pfizer execs have informed the company's investors of a "significant opportunity" to hike the prices of the Pfizer-BioNTech vaccine. Speaking at the virtual Barclays Global Healthcare Conference last week, two high-ranking Pfizer employees – CFO Frank D'Amelio and Chuck Triano, senior VP of investor relations – said there would be a chance for Pfizer to raise prices for the vaccine when COVID moves from a pandemic state to an endemic situation and the virus circulates continually in pockets around the globe.

Pfizer execs say there's a 'significant opportunity' to hike prices of its COVID vaccine

BHP Billiton

Kraft Heinz

Philip Morris

AT&T

High-dividend names are some of the best retirement stocks and can be a good way to achieve strong long-term growth for your portfolio. The post 7 High-Yield Stocks for Your Retirement Nest Egg appeared first on InvestorPlace.

7 High-Yield Stocks for Your Retirement Nest Egg

Viatris

It's been a rough start for the combined generic drug company.

Should Pfizer's and Mylan's Shareholders Sell Their Shares of Viatris?

Johnson & Johnson

Don't jump to any conclusions based on the different vaccines' advisory committee votes.

Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines?

Pfizer Inc.'s stock may have lost ground last year, and so far this year, while its peer group gained ground, but 2020 could still be considered a good year for the health care company, as it developed, along with its partner BioNTech SE , one of the three COVID-19 vaccines in use in the U.S. It was certainly a good year for Chief Executive Albert Bourla, whose total compensation increased 17.3% to $21,033,570, from $17,928,963 in 2019, according to a proxy filing on Friday. His 2020 compensation included a salary of $1,650,000, was well as option award, non-equity incentive plan compensation and stock awards.

Pfizer CEO compensation jumped 17% in 2020, as COVID-19 vaccine was developed but stock fell

COMPASS Pathways

Illumina

ResMed

Teladoc

Thermo Fisher Scientific

These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy and Hold for the Long Term

Pfizer Inc. (PFE) Management Presents at Barclays Global Healthcare Conference (Transcript)

Pfizer Inc (NYSE: PFE) says it is not currently talking to India over local production, and it will consider making its COVID-19 vaccine outside the U.S. and Europe only after the “pandemic supply phase” is over, Reuters reports. The comments came after Reuters reported that Pfizer told the Indian government it wanted to produce the shot locally if assured of faster regulatory clearance and freedom on pricing and exports.

Pfizer To Contemplate Additional Production Sites After Pandemic-Related Pressure Is Over: Reuters

Results from Israel suggest the Pfizer-BioNTech vaccine works even better than its phase 3 trial results indicated.

Pfizer's Vaccine 97% Effective at Preventing COVID-19 in Real-World Study

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said that real-world data from Israel suggests that their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, thus having the potential to reduce transmission significantly. The companies also said the latest analysis of the Israeli data showed the vaccine was 97% effective in preventing symptomatic disease, severe disease, and death, in line with the 95% efficacy reported in December.

Pfizer/BioNTech's COVID-19 Vaccine Can Prevent Asymptomatic Infection, Study Shows

Pfizer said its Covid-19 vaccine blocked 94% of asymptomatic infections in an Israeli study – a result CEO Albert Bourla called "extremely important."

Pfizer Covid vaccine blocks 94% of asymptomatic infections and 97% of symptomatic cases in Israeli study

Pfizer and its German partner BioNTech have indicated that they should have the capacity to produce as many as three billion doses of their Covid-19 vaccine in 2022, subject to demand. For perspective, Pfizer intends to produce about 2 billion doses of its shot this year and is projecting about.

Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?

Pfizer Inc. and BioNTech SE , along with the Israel Ministry of Health, said a real-world study showed "dramatically lower" rates of COVID-19 cases in people vaccinated with the companies' BNT162b2 vaccine. The data also showed that protection from COVID-19 is even stronger two weeks after the second dose was taken.

Pfizer, BioNTech real-world study shows COVID-19 vaccine 'dramatically' lowers cases, hospitalizations and deaths

JERUSALEM, NEW YORK and MAINZ, GERMANY, March 11, 2021 -  The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel's nationwide immunization program. These new data build upon and confirm previously released data from the MoH demonstrating the vaccine's effectiveness in preventing symptomatic SARS-CoV-2 infections, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The latest analysis from the MoH proves that two weeks after the second vaccine dose protection is even stronger – vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death. This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) declared COVID-19 a pandemic.

Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared

Deere & Company

Healthpeak Properties

PepsiCo

Starbucks

Verizon

WestRock

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Despite the COVID-19 pandemic, dividend income continues to grow, due primarily to additional investment and reinvestment. November through February 2021 proved to be pivotal moments for dividend investors, due to massive dividend increases.

Dividend Stock Purchase: Lanny's February 2021 Summary

The European Commission has reportedly reached a deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to supply an additional four million COVID-19 vaccine doses be delivered in March.  According to Reuters, this additional supply deal is expected to ease border movement and tackle virus hotspots.

News for Pfizer Stock (PFE)